Načítá se...
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
BACKGROUND: A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG). METHODS: Sixty patients with recurrent HGG received temozolomide at 150 mg/m(2)/day on days 1–7 and days 15–21 duri...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4136897/ https://ncbi.nlm.nih.gov/pubmed/24670608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou044 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|